000739 普洛药业
已收盘 08-28 15:00:00
资讯
新帖
简况
普洛药业涨5.89%，开源证券四日前给出“买入”评级
证券之星 · 08-25
普洛药业涨5.89%，开源证券四日前给出“买入”评级
开源证券：给予普洛药业买入评级
证券之星 · 08-21
开源证券：给予普洛药业买入评级
8月21日普洛药业跌5.56%，大成睿享混合A基金重仓该股
证券之星 · 08-21
8月21日普洛药业跌5.56%，大成睿享混合A基金重仓该股
普洛药业（000739）2026年中报简析：净利润同比下降7.22%，应收账款上升
证券之星 · 08-21
普洛药业（000739）2026年中报简析：净利润同比下降7.22%，应收账款上升
普洛药业（000739）披露控股股东一致行动人增持计划时间过半进展公告，8月19日股价下跌1.34%
证券之星 · 08-19
普洛药业（000739）披露控股股东一致行动人增持计划时间过半进展公告，8月19日股价下跌1.34%
普洛药业最新公告：子公司获己酮可可碱缓释片药品注册证书
证券之星 · 08-10
普洛药业最新公告：子公司获己酮可可碱缓释片药品注册证书
股市必读：普洛药业新发布《关于获得化学原料药上市申请批准通知书的公告》
证券之星 · 08-07
股市必读：普洛药业新发布《关于获得化学原料药上市申请批准通知书的公告》
普洛药业最新公告：子公司获氟泽雷塞原料药上市申请批准
证券之星 · 08-05
普洛药业最新公告：子公司获氟泽雷塞原料药上市申请批准
普洛药业：近期与剂泰科技签署战略合作框架协议
南方财经网 · 08-03
普洛药业：近期与剂泰科技签署战略合作框架协议
公司问答丨普洛药业：2025年度出口美国的仿制药占公司药品业务收入的1%左右
格隆汇 · 07-29
公司问答丨普洛药业：2025年度出口美国的仿制药占公司药品业务收入的1%左右
普洛药业(000739.SZ)子公司获得左卡尼汀口服溶液药品注册证书
智通财经 · 07-28
普洛药业(000739.SZ)子公司获得左卡尼汀口服溶液药品注册证书
普洛药业最新公告：控股子公司与药明生物、多宁生物签署战略合作框架协议
证券之星 · 07-27
普洛药业最新公告：控股子公司与药明生物、多宁生物签署战略合作框架协议
普洛药业最新公告：子公司加巴喷丁原料药获欧洲CEP证书
证券之星 · 07-22
普洛药业最新公告：子公司加巴喷丁原料药获欧洲CEP证书
7月17日普洛药业跌6.43%，大成睿享混合A基金重仓该股
证券之星 · 07-17
7月17日普洛药业跌6.43%，大成睿享混合A基金重仓该股
普洛药业（000739）披露对外投资暨关联交易公告，7月16日股价上涨2.59%
证券之星 · 07-16
普洛药业（000739）披露对外投资暨关联交易公告，7月16日股价上涨2.59%
普洛药业最新公告：拟与关联方共同投资设立生物技术公司
证券之星 · 07-16
普洛药业最新公告：拟与关联方共同投资设立生物技术公司
7月15日普洛药业涨7.23%，大成睿享混合A基金重仓该股
证券之星 · 07-15
7月15日普洛药业涨7.23%，大成睿享混合A基金重仓该股
普洛药业：本次新增纳入国家基本药物目录（2026年版）的有7个品种、10个产品
证券之星 · 07-15
普洛药业：本次新增纳入国家基本药物目录（2026年版）的有7个品种、10个产品
普洛药业获得发明专利授权：“一种去除D-组分杂质提高磷酸替米考星质量的方法及其应用”
证券之星 · 07-15
普洛药业获得发明专利授权：“一种去除D-组分杂质提高磷酸替米考星质量的方法及其应用”
普洛药业：该项目生产线技改已经完工
证券之星 · 07-02
普洛药业：该项目生产线技改已经完工
加载更多
公司概况
公司名称：
普洛药业股份有限公司
所属行业：
医药制造业
上市日期：
1997-05-09
主营业务：
普洛药业股份有限公司的主营业务是创新药研发生产服务（CDMO）、原料药中间体、药品等研发、生产和销售以及进出口贸易业务。公司的主要产品是原料药中间体、创新药研发生产服务、药品。
发行价格：
5.70
{"stockData":{"symbol":"000739","market":"SZ","secType":"STK","nameCN":"普洛药业","latestPrice":21.33,"timestamp":1787900619000,"preClose":21.54,"halted":0,"volume":14413863,"delay":0,"changeRate":-0.0097,"floatShares":1158000000,"shares":1158000000,"eps":0.7338,"marketStatus":"已收盘","change":-0.21,"latestTime":"08-28 15:00:00","open":21.53,"high":22.1,"low":21.32,"amount":313000000,"amplitude":0.0362,"askPrice":21.34,"askSize":173,"bidPrice":21.33,"bidSize":248,"shortable":0,"etf":0,"ttmEps":0.7338,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":5,"adr":0,"adjPreClose":21.54,"symbolType":"stock","openAndCloseTimeList":[[1787880600000,1787887800000],[1787893200000,1787900400000]],"highLimit":23.69,"lowLimit":19.39,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1158443576,"isCdr":false,"pbRate":3.8,"roa":"--","peRate":29.067866,"roe":"8.05%","epsLYR":0.7723,"committee":0.614414,"marketValue":24710000000,"turnoverRate":0.0124,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-08-31。","floatMarketCap":24700000000},"requestUrl":"/m/hq/s/000739","defaultTab":"news","newsList":[{"id":"2662978224","title":"普洛药业涨5.89%，开源证券四日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662978224","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662978224?lang=zh_cn&edition=full","pubTime":"2026-08-25 16:37","pubTimestamp":1787647071,"startTime":"0","endTime":"0","summary":"今日普洛药业涨5.89%，收盘报20.87元。2026年8月21日，开源证券研究员余汝意,阮帅发布了对普洛药业的研报《公司信息更新报告：CDMO业绩较快增长，盈利能力持续提高》，该研报对普洛药业给出“买入”评级。研报中预计2026-2028年归母净利润为10.25/12.43/15.21亿元，当前股价对应PE为23.4/19.3/15.8倍，估值性价比高，考虑公司CDMO业务较快增长且在手订单规模较大，维持“买入”评级。普洛药业个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500033775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661429542","title":"开源证券：给予普洛药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2661429542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661429542?lang=zh_cn&edition=full","pubTime":"2026-08-21 22:01","pubTimestamp":1787320865,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,阮帅近期对普洛药业进行研究并发布了研究报告《公司信息更新报告：CDMO业绩较快增长，盈利能力持续提高》，给予普洛药业买入评级。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为28.0。本文数据来源于开源证券股份有限公司，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100044868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661652262","title":"8月21日普洛药业跌5.56%，大成睿享混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661652262","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661652262?lang=zh_cn&edition=full","pubTime":"2026-08-21 16:43","pubTimestamp":1787301791,"startTime":"0","endTime":"0","summary":"证券之星消息，8月21日普洛药业跌5.56%，收盘报20.72元，换手率3.19%，成交量36.98万手，成交额7.87亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共20家，其中持有数量最多的公募基金为大成基金的大成睿享混合A。大成睿享混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100029580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","BK0239","000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661230908","title":"普洛药业（000739）2026年中报简析：净利润同比下降7.22%，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2661230908","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661230908?lang=zh_cn&edition=full","pubTime":"2026-08-21 06:09","pubTimestamp":1787263792,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期普洛药业发布2026年中报。截至本报告期末，公司营业总收入48.23亿元，同比下降11.41%，归母净利润5.22亿元，同比下降7.22%。按单季度数据看，第二季度营业总收入23.76亿元，同比下降12.47%，第二季度归母净利润2.73亿元，同比下降13.08%。本报告期普洛药业应收账款上升，应收账款同比增幅达30.56%。本文数据来源于普洛药业2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100004843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660294314","title":"普洛药业（000739）披露控股股东一致行动人增持计划时间过半进展公告，8月19日股价下跌1.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660294314","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660294314?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:26","pubTimestamp":1787149577,"startTime":"0","endTime":"0","summary":"近日，普洛药业股份有限公司发布《关于控股股东一致行动人增持股份计划时间过半的进展公告》。公告显示，公司控股股东一致行动人东阳市横店禹山运动休闲有限公司自2026年5月20日起6个月内，计划增持公司股份金额不低于6,000万元，不超过12,000万元。截至公告日，增持计划时间过半，禹山运动已累计增持公司股份6,057,900股，占公司总股本的0.52%，累计增持金额100,021,080元。增持后，控股股东及其一致行动人合计持有公司股份614,155,308股，占公司总股本的53.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900043324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000739","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658149984","title":"普洛药业最新公告：子公司获己酮可可碱缓释片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2658149984","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658149984?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:26","pubTimestamp":1786354019,"startTime":"0","endTime":"0","summary":"普洛药业(000739.SZ)公告称，公司控股子公司康裕制药收到药监局签发的己酮可可碱缓释片《药品注册证书》。己酮可可碱缓释片为周围血管扩张药。用于周围性血管疾病，包括间歇性跛行和静息疼痛。根据相关数据显示，己酮可可碱缓释片2025年度国内市场规模约为5227万片，销售金额约为2.62亿元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000022170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","BK0239","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657594786","title":"股市必读：普洛药业新发布《关于获得化学原料药上市申请批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657594786","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657594786?lang=zh_cn&edition=full","pubTime":"2026-08-07 01:36","pubTimestamp":1786037773,"startTime":"0","endTime":"0","summary":"公司公告汇总：全资子公司浙江普洛家园药业有限公司获氟泽雷塞原料药《化学原料药上市申请批准通知书》，该原料药对应制剂已纳入2025年底国家医保药品目录。公司公告汇总关于获得化学原料药上市申请批准通知书的公告普洛药业全资子公司浙江普洛家园药业有限公司收到国家药品监督管理局签发的氟泽雷塞原料药《化学原料药上市申请批准通知书》，审批结论为符合药品注册有关要求，批准注册。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700001703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0188","000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510377","title":"普洛药业最新公告：子公司获氟泽雷塞原料药上市申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510377","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657510377?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:51","pubTimestamp":1785923506,"startTime":"0","endTime":"0","summary":"普洛药业(000739.SZ)公告称，公司全资子公司浙江普洛家园药业收到国家药监局签发的氟泽雷塞原料药《化学原料药上市申请批准通知书》。该原料药用于治疗KRASG12C突变型晚期非小细胞肺癌成人患者，其片剂已于2024年8月在中国获批上市，并于2025年底纳入国家医保目录。此次获批将保障原料药供应，助力合作伙伴产品开发，对公司CDMO业务及未来经营产生积极影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500033066.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0188","000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656573324","title":"普洛药业：近期与剂泰科技签署战略合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2656573324","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656573324?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:32","pubTimestamp":1785745920,"startTime":"0","endTime":"0","summary":"南财智讯8月3日电，普洛药业公告，公司近期与剂泰科技（北京）股份有限公司签署战略合作框架协议，双方将在CDMO服务、资本与产业协同、改良型新药联合开发等领域开展长期合作。本次协议为框架性协议，不涉及具体交易金额，对公司本年度经营业绩不构成重大影响；若后续具体业务顺利推进，将对公司未来经营业绩产生积极影响。协议履行存在不确定性及政策、市场环境变化等风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608033829811151.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608033829811151.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK0060","BK0239","000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655854630","title":"公司问答丨普洛药业：2025年度出口美国的仿制药占公司药品业务收入的1%左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2655854630","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655854630?lang=zh_cn&edition=full","pubTime":"2026-07-29 14:54","pubTimestamp":1785308045,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0060","BK0239","000739","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654702010","title":"普洛药业(000739.SZ)子公司获得左卡尼汀口服溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2654702010","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654702010?lang=zh_cn&edition=full","pubTime":"2026-07-28 17:34","pubTimestamp":1785231263,"startTime":"0","endTime":"0","summary":"智通财经APP讯，普洛药业(000739.SZ)发布公告，公司控股子公司浙江普洛康裕制药有限公司(以下简称“康裕制药”)收到国家药品监督管理局(以下简称 “药监局”)签发的左卡尼汀口服溶液《药品注册证书》。左卡尼汀口服溶液用于治疗原发性系统性卡尼汀缺乏症，也用于先天性代谢异常导致的继发性卡尼汀缺乏症的短期和长期治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"普洛药业(000739.SZ)子公司获得左卡尼汀口服溶液药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0188","BK0239","000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654011748","title":"普洛药业最新公告：控股子公司与药明生物、多宁生物签署战略合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2654011748","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654011748?lang=zh_cn&edition=full","pubTime":"2026-07-27 18:51","pubTimestamp":1785149471,"startTime":"0","endTime":"0","summary":"普洛药业(000739.SZ)公告称，公司控股子公司浙江安特禹泰生物技术有限公司与上海药明生物技术有限公司、上海多宁生物科技股份有限公司签署《战略合作框架协议》，三方拟建立长期战略合作关系，推动生物大分子药物管线开发、产业化能力建设及供应链体系完善。协议有效期五年，不涉及具体项目和金额，对公司本年度经营业绩不构成重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700027363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0823426308.USD","LU1794554557.SGD","LU0456827905.SGD","LU0516423174.USD","BK0188","02269","BK1576","LU0359202008.SGD","LU0708995583.HKD","LU0307460666.USD","LU0181495838.USD","LU0348825331.USD","KURE","LU0140636845.USD","BK1610","LU0320764599.SGD","LU0348735423.USD","LU1242518857.USD","LU0979878070.USD","LU2039709279.SGD","LU0516422952.EUR","LU0856984785.SGD","LU1688375341.USD","000739","LU0051755006.USD","LU0516422440.USD","LU0043850808.USD","LU0516423091.SGD","LU0417516738.SGD","IE00B0JY6N72.USD","SG9999002463.SGD","LU0516422366.SGD","BK1589","LU0039217434.USD","LU0819121731.USD","BK1521","LU0572944931.SGD","LU0456846285.SGD","LU0326950275.SGD","LU0327786744.USD","SG9999002562.SGD","LU0052750758.USD","LU0823426480.USD","LU0359201612.USD","LU1720050803.USD","BK0239","LU0417516902.SGD","LU0588546209.SGD","LU3063872942.SGD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653245754","title":"普洛药业最新公告：子公司加巴喷丁原料药获欧洲CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2653245754","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653245754?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:00","pubTimestamp":1784718042,"startTime":"0","endTime":"0","summary":"普洛药业(000739.SZ)公告称，公司全资子公司浙江普洛家园药业有限公司收到欧洲药品质量管理局签发的加巴喷丁原料药欧洲药典适用性证书。该证书自2026年7月10日起生效，表明该产品具备进入欧盟及承认CEP证书的其他市场的资质，有助于拓展国际市场。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200040617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000739","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652405002","title":"7月17日普洛药业跌6.43%，大成睿享混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652405002","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652405002?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:38","pubTimestamp":1784277490,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日普洛药业跌6.43%，收盘报19.65元，换手率3.05%，成交量35.3万手，成交额7.07亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共20家，其中持有数量最多的公募基金为大成基金的大成睿享混合A。大成睿享混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000739","BK0188","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651440937","title":"普洛药业（000739）披露对外投资暨关联交易公告，7月16日股价上涨2.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651440937","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651440937?lang=zh_cn&edition=full","pubTime":"2026-07-16 22:07","pubTimestamp":1784210837,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘，普洛药业报收于21.0元，较前一交易日上涨2.59%，最新总市值为243.27亿元。该股当日开盘20.55元，最高21.5元，最低19.61元，成交额达10.27亿元，换手率为4.28%。近日，普洛药业股份有限公司披露《关于对外投资暨关联交易的公告》。公司拟认缴出资3,457,800元，占股34.578%。因合作方为公司关联方，本次投资构成关联交易。本次投资旨在拓展生物药业务布局，提升公司综合竞争力。该事项无需提交董事会或股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600039996.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","000739","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651443600","title":"普洛药业最新公告：拟与关联方共同投资设立生物技术公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2651443600","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651443600?lang=zh_cn&edition=full","pubTime":"2026-07-16 18:01","pubTimestamp":1784196102,"startTime":"0","endTime":"0","summary":"普洛药业(000739.SZ)公告称，公司拟与横店有限公司等关联方共同投资设立浙江安特禹泰生物技术有限公司，注册资本1000万元，其中公司认缴出资345.78万元，占34.578%股权。本次投资构成关联交易，旨在拓展生物药业务布局，提升综合竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600031755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0060","000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651745346","title":"7月15日普洛药业涨7.23%，大成睿享混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651745346","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651745346?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:27","pubTimestamp":1784104032,"startTime":"0","endTime":"0","summary":"证券之星消息，7月15日普洛药业涨7.23%创60日新高，收盘报20.47元，换手率4.23%，成交量48.94万手，成交额9.98亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共20家，其中持有数量最多的公募基金为大成基金的大成睿享混合A。大成睿享混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500030957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","BK0060","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651976430","title":"普洛药业：本次新增纳入国家基本药物目录（2026年版）的有7个品种、10个产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2651976430","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651976430?lang=zh_cn&edition=full","pubTime":"2026-07-15 15:21","pubTimestamp":1784100072,"startTime":"0","endTime":"0","summary":"公司本次新增纳入国家基本药物目录的有7个品种、10个产品，分别是琥珀酸美托洛尔缓释片、左乙拉西坦片、左氧氟沙星片、吸入用乙酰半胱氨酸溶液、头孢克肟颗粒、头孢克肟分散片、头孢克肟胶囊、头孢克肟片、奥司他韦干混悬剂、丙戊酸钠缓释片。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500023692.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000739","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651486329","title":"普洛药业获得发明专利授权：“一种去除D-组分杂质提高磷酸替米考星质量的方法及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2651486329","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651486329?lang=zh_cn&edition=full","pubTime":"2026-07-15 03:26","pubTimestamp":1784057218,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示普洛药业新获得一项发明专利授权，专利名为“一种去除D-组分杂质提高磷酸替米考星质量的方法及其应用”，专利申请号为CN202211329783.9，授权日为2026年7月14日。今年以来普洛药业新获得专利授权7个，较去年同期增加了250%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500004865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000739","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648252710","title":"普洛药业：该项目生产线技改已经完工","url":"https://stock-news.laohu8.com/highlight/detail?id=2648252710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648252710?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:27","pubTimestamp":1782952036,"startTime":"0","endTime":"0","summary":"证券之星消息，普洛药业(000739)07月02日在投资者关系平台上答复投资者关心的问题。投资者提问：医美化妆品原料业务板块，年产20吨ZS25066A、100吨ZS25067A生产线技改项目进展如何？能否按期完工，助力公司拓展医美领域业务，实现26/27年10亿医美业务目标？普洛药业回复：投资者您好！该项目生产线技改已经完工，目前项目已开始商业化生产。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200005706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","000739","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787979484655,"stockEarnings":[{"period":"1week","weight":0.0294},{"period":"1month","weight":0.0324},{"period":"3month","weight":0.2842},{"period":"6month","weight":0.1952},{"period":"1year","weight":0.3908},{"period":"ytd","weight":0.3274}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.0323},{"period":"3month","weight":-0.0286},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0283},{"period":"ytd","weight":-0.0042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"普洛药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"36793人(较上一季度增加9.11%)","perCapita":"31472股","listingDate":"1997-05-09","address":"浙江省金华市东阳市横店江南路399号","registeredCapital":"115844万元","survey":" 普洛药业股份有限公司的主营业务是创新药研发生产服务（CDMO）、原料药中间体、药品等研发、生产和销售以及进出口贸易业务。公司的主要产品是原料药中间体、创新药研发生产服务、药品。","listedPrice":5.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"普洛药业(000739)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供普洛药业(000739)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"普洛药业,000739,普洛药业股票,普洛药业股票老虎,普洛药业股票老虎国际,普洛药业行情,普洛药业股票行情,普洛药业股价,普洛药业股市,普洛药业股票价格,普洛药业股票交易,普洛药业股票购买,普洛药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"普洛药业(000739)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供普洛药业(000739)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}